24.03.2020
Biofourmis, a developer of digital therapeutics aimed to personalized care, says its technology is being used in a remote-monitoring and disease-surveillance program in Hong Kong involving patients with diagnosed or suspected novel coronavirus disease (COVID-19).
The program, administered by the University of Hong Kong, also includes Hong Kong-based Harmony Medical, which is Biofourmis’s joint-venture partner for the China region.
Patients potentially infected with COVID-19 are being monitored with the Biofourmis Biovitals Sentinel platform, a system the company built in less than two weeks specifically for this initiative by customizing its FDA-cleared artificial intelligence-powered Biovitals Analytics platform.
Biovitals Sentinel’s 24/7 remote-monitoring technology and analytics are providing clinicians involved in the COVID-19 program with clinical-decision support for early identification of any physiological changes that could indicate deterioration, and in order to enable earlier interventions for better outcomes.